Veeva Systems Inc. VEEV R3KPHARMA
Company Overview
Veeva Systems Inc. provides cloud-based software for the life sciences industry in North America, Europe, the Asia Pacific, the Middle East, Africa, and Latin America. The company offers Veeva Commercial Cloud comprising Veeva Vault CRM Suite for pharmaceutical and biotechnology companies; Veeva Medical that provides source of medical content across multiple channels and geographies; Veeva PromoMats, an end-to-end content and digital asset management solution; and Veeva Crossix, an analytics platform for pharmaceutical brands. It also provides Veeva Data Cloud, such as Veeva OpenData, a customer reference data solution; Veeva Link, which provides deep data; Veeva Compass, which includes de-identified and longitudinal patient data; and Veeva CRM Pulse that provides access and multichannel engagement metrics. In addition, the company offers Veeva Development Cloud consisting of Veeva Clinical Platform, which advances clinical trial execution; Veeva Clinical Data Management that helps sponsors and CROs design and run trials; Veeva Safety, which unifies systems and processes; Veeva RIM that provides regulatory information management capabilities, as well as Veeva Quality Cloud, which is used by the life sciences and consumer products industries; and Veeva Business Consulting services. Further, it provides professional and support services, including implementation and deployment planning, and project management; requirements analysis, solution design, and configuration; systems environment management and deployment; services focused on advancing or transforming business and operating processes; technical consulting services on data migration and systems integrations; training; and ongoing managed services, such as outsourced systems administration. The company was formerly known as Verticals onDemand, Inc. and changed its name to Veeva Systems Inc. in April 2009. Veeva Systems Inc. was incorporated in 2007 and is headquartered in Pleasanton, California.
Why Investors Should Care
Net profit has compounded at 51.1% per year over the last five years.
Revenue has grown at a 35.5% CAGR over the past five years.
Maintains a net profit margin of 29.3%.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Jan 2026 Revenue of $3.20B (+16.3% YoY); net profit $908.91M.
- Trailing 12 Months Year-on-year growth — revenue +17.6%, earnings +39.5%.
- 5-Year Trend Long-term compounding — revenue CAGR 35.5%, profit CAGR 51.1%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 35.55% |
| 1 Year: | 17.60% |
Compounded Profit Growth
| 5 Years: | 51.15% |
| 1 Year: | 39.50% |
Stock Price Performance
| 1 Year: | -5.14% |
| 6 Months: | +35.42% |
| 3 Months: | +58.36% |
| 1 Month: | +14.91% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- Golden Cross10d ago
- RSI (14)58.66 · Neutral
P/E of 43.49 is above the sector median of 24.83 — pricier than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Excellent profit margin of 29.3%.
- Compounding revenue at 35.5% over 5 years.
- Profit CAGR of 51.1% over 5 years.
- Generates positive free cash flow.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | VEEV Veeva Systems Inc. R3KPHARMA | 264.84 | 43.49 | $42.88B | 0.00% | 12.48% | 14.42% | 35.55% | 51.15% |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Jul 2015 | Oct 2015 | Jan 2016 | Apr 2016 | Jul 2016 | Oct 2016 | Jan 2017 | Apr 2017 | Jul 2017 | Oct 2017 | Jan 2018 | Apr 2018 | Jul 2018 | Oct 2018 | Jan 2019 | Apr 2019 | Jul 2019 | Oct 2019 | Jan 2020 | Apr 2020 | Jul 2020 | Oct 2020 | Jan 2021 | Apr 2021 | Jul 2021 | Oct 2021 | Apr 2022 | Jul 2022 | Oct 2022 | Apr 2023 | Jul 2023 | Oct 2023 | Apr 2024 | Jul 2024 | Oct 2024 | Apr 2025 | Jul 2025 | Oct 2025 | Jan 2026 | Apr 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | 167.79M | 177.01M | - | 195.55M | 209.61M | 224.73M | - | 244.75M | 266.90M | 280.92M | 311.51M | 337.11M | 353.68M | 377.52M | 396.76M | 433.57M | 455.59M | 476.11M | 505.10M | 534.22M | 552.35M | 526.33M | 590.23M | 616.50M | 650.35M | 676.18M | 699.21M | 759.04M | 789.08M | 811.24M | 835.95M | 882.95M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 173.82M | 195.25M | 199.47M | 213.48M | 220.92M |
| Gross Profit | 64.63M | 69.91M | 74.53M | 78.67M | 89.15M | 98.85M | 103.68M | 110.89M | 117.39M | 123.77M | 127.07M | 135.39M | 150.38M | 163.36M | 167.80M | 179.25M | 196.68M | 207.59M | 217.19M | 242.23M | 256.48M | 274.52M | 282.91M | 317.44M | 333.50M | 346.55M | 365.59M | 382.55M | 398.44M | 359.66M | 421.21M | 448.82M | 476.46M | 505.81M | 524.82M | 585.22M | 593.83M | 611.77M | 622.47M | 662.02M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 351.49M | 397.92M | 370.92M | 376.60M | 388.91M |
| Operating Income | 22.35M | 20.10M | 15.21M | 17.81M | 23.82M | 33.81M | 32.53M | 38.86M | 38.07M | 42.49M | 38.50M | 43.96M | 52.82M | 63.09M | 63.00M | 71.17M | 73.86M | 80.80M | 60.39M | 87.56M | 90.08M | 101.31M | 98.84M | 128.45M | 124.62M | 132.71M | 127.67M | 101.09M | 121.40M | 61.53M | 104.05M | 128.49M | 155.17M | 166.49M | 181.35M | 233.73M | 195.91M | 240.85M | 245.88M | 273.11M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 243.55M | 206.03M | 250.56M | 254.19M | 284.70M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 298.82M | 265.36M | 312.79M | 317.54M | 347.53M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 70.63M | 65.06M | 76.58M | 73.33M | 86.59M |
| Net Income | 13.41M | 10.48M | 17.59M | 12.51M | 12.96M | 21.63M | 21.71M | 37.00M | 38.60M | 34.92M | 40.65M | 44.31M | 50.29M | 64.08M | 71.15M | 73.45M | 79.24M | 82.25M | 66.18M | 86.57M | 93.55M | 96.96M | 102.92M | 115.57M | 108.86M | 105.87M | 100.11M | 90.60M | 108.46M | 131.52M | 111.63M | 135.16M | 161.66M | 171.04M | 185.81M | 228.19M | 200.31M | 236.20M | 244.20M | 260.94M |
| Diluted EPS | 0.09 | 0.07 | 0.12 | 0.09 | 0.09 | 0.15 | 0.15 | 0.24 | 0.25 | 0.23 | 0.26 | 0.29 | 0.32 | 0.41 | 0.45 | 0.47 | 0.50 | 0.52 | 0.42 | 0.54 | 0.58 | 0.60 | 0.64 | 0.71 | 0.67 | 0.65 | 0.62 | 0.56 | 0.67 | 0.81 | 0.68 | 0.83 | 0.98 | 1.04 | 1.13 | 1.37 | 1.19 | 1.40 | 1.45 | 1.57 |
| R&D Expense | 15.26M | 17.67M | - | 22.07M | 23.56M | 25.01M | - | 28.31M | 32.68M | 34.03M | - | 37.20M | 38.83M | 40.00M | - | 44.97M | 51.15M | 52.58M | - | 62.24M | 70.05M | 79.99M | - | 83.23M | 94.90M | 98.64M | 113.47M | 134.01M | 130.26M | 146.96M | 157.23M | 161.28M | 162.71M | 176.43M | 172.41M | 184.03M | 192.68M | 191.88M | - | 208.32M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Jan 2012 | Jan 2013 | Jan 2014 | Jan 2015 | Jan 2016 | Jan 2017 | Jan 2018 | Jan 2019 | Jan 2020 | Jan 2021 | Jan 2022 | Jan 2023 | Jan 2024 | Jan 2025 | Jan 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 61.26M | 129.55M | 210.15M | 313.22M | 409.22M | 550.54M | 690.56M | 862.21M | 1.10B | 1.47B | - | 2.16B | 2.36B | 2.75B | 3.20B |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | 609.40M | 677.29M | 699.64M | 782.02M |
| Gross Profit | 32.21M | 72.53M | 127.55M | 197.56M | 267.01M | 376.86M | 479.14M | 616.93M | 800.71M | 1.06B | - | 1.55B | 1.69B | 2.05B | 2.41B |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | 1.09B | 1.26B | 1.36B | 1.50B |
| Operating Income | 6.64M | 30.03M | 39.30M | 69.97M | 78.59M | 120.69M | 157.93M | 222.87M | 286.22M | 377.79M | - | 459.09M | 429.33M | 691.43M | 916.37M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | 488.21M | 461.96M | 730.82M | 954.34M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | 509.10M | 588.02M | 919.38M | 1.19B |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | 21.39M | 62.32M | 205.24M | 285.60M |
| Net Income | 4.23M | 18.78M | 23.61M | 40.38M | 54.46M | 77.57M | 151.18M | 229.83M | 301.12M | 380.00M | - | 487.71M | 525.71M | 714.14M | 908.91M |
| Diluted EPS | 0.02 | 0.11 | 0.15 | 0.28 | 0.38 | 0.53 | 0.98 | 1.47 | 1.90 | 2.36 | - | 3.00 | 3.22 | 4.32 | 5.44 |
| R&D Expense | 7.75M | 14.64M | 26.33M | 41.16M | 65.98M | 96.74M | 132.02M | 158.78M | 209.90M | 294.22M | 382.04M | 520.28M | 629.03M | 693.08M | 767.39M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Jan 2011 | Jan 2012 | Jan 2013 | Jan 2014 | Dec 2014 | Jan 2015 | Jan 2016 | Jan 2017 | Jan 2018 | Jan 2019 | Jan 2020 | Jan 2021 | Jan 2022 | Jan 2023 | Jan 2024 | Jan 2025 | Jan 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 89.82M | 370.31M | - | 544.89M | 705.80M | 917.38M | 1.23B | 1.65B | 2.27B | 3.05B | - | 4.80B | 5.91B | 7.34B | 8.98B |
| Current Assets | - | - | - | - | - | - | - | - | - | - | - | - | - | 3.97B | 5.00B | 6.31B | 8.00B |
| Cash & Equivalents | 13.78M | 16.88M | 31.89M | 262.51M | 262.51M | 129.25M | 132.18M | 217.61M | 320.18M | 550.97M | 476.73M | 730.50M | - | 886.47M | 703.49M | 1.12B | 1.42B |
| Inventory | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Receivables | - | - | - | - | - | - | - | - | - | - | - | - | - | 703.05M | 852.17M | 1.02B | 1.26B |
| Total Liabilities | - | - | 55.85M | 90.21M | - | 138.06M | 200.55M | 264.72M | 324.10M | 416.02M | 606.18M | 779.75M | - | 1.09B | 1.27B | 1.51B | 1.76B |
| Current Liabilities | - | - | 54.29M | 86.62M | - | 135.52M | 186.28M | 246.78M | 306.17M | 401.02M | 551.17M | 715.95M | - | 1.01B | 1.18B | 1.40B | 1.64B |
| Long Term Debt | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Total Debt | - | - | - | - | - | - | - | - | - | - | - | - | - | 60.98M | 55.77M | 75.78M | 95.86M |
| Total Equity | 9.17M | 14.10M | 33.97M | 280.10M | - | 406.83M | 521.98M | 678.15M | 906.24M | 1.24B | 1.67B | 2.27B | - | 3.72B | 4.64B | 5.83B | 7.21B |
| Shares Outstanding | - | - | - | - | - | - | - | - | - | - | - | - | - | 158.24M | 161.26M | 162.58M | 163.78M |
Cash Flows (Annual)
Figures in USD.
| Metric | Jan 2012 | Jan 2013 | Jan 2014 | Jan 2015 | Jan 2016 | Jan 2017 | Jan 2018 | Jan 2019 | Jan 2020 | Jan 2021 | Jan 2022 | Jan 2023 | Jan 2024 | Jan 2025 | Jan 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | 4.74M | 30.80M | 41.75M | - | - | 144.01M | 233.44M | 310.83M | 437.38M | 551.25M | - | 780.47M | 911.34M | 1.09B | 1.42B |
| Investing Cash Flow | -1.68M | -16.36M | -26.58M | - | - | -96.75M | -154.52M | -103.87M | -516.91M | -333.63M | - | -1.01B | -1.08B | -700.14M | -1.10B |
| Financing Cash Flow | 49.00K | 575.00K | 215.44M | - | - | 37.98M | 20.77M | 25.91M | 10.01M | 33.82M | - | -19.38M | -16.19M | 26.11M | -9.33M |
| Capital Expenditure | -650.00K | -964.00K | -1.86M | -26.53M | -21.15M | -6.92M | -9.63M | -8.44M | -3.11M | - | - | - | - | - | - |
| Free Cash Flow | 4.09M | 29.84M | 39.89M | - | - | 137.09M | 223.81M | 302.39M | 434.26M | - | - | 780.47M | 911.34M | 1.09B | 1.42B |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | - | - | -246.59M | -181.20M | 416.03M | 301.53M |
| Share Buybacks | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 169.95M |
Ratios (Annual)
Figures in %.
| Metric | Jan 2012 | Jan 2013 | Jan 2014 | Jan 2015 | Jan 2016 | Jan 2017 | Jan 2018 | Jan 2019 | Jan 2020 | Jan 2021 | Jan 2022 | Jan 2023 | Jan 2024 | Jan 2025 | Jan 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 52.6% | 56.0% | 60.7% | 63.1% | 65.2% | 68.5% | 69.4% | 71.6% | 72.5% | 72.1% | - | 71.7% | 71.3% | 74.5% | 75.5% |
| Operating Margin % | 10.8% | 23.2% | 18.7% | 22.3% | 19.2% | 21.9% | 22.9% | 25.8% | 25.9% | 25.8% | - | 21.3% | 18.2% | 25.2% | 28.7% |
| Net Margin % | 6.9% | 14.5% | 11.2% | 12.9% | 13.3% | 14.1% | 21.9% | 26.7% | 27.3% | 25.9% | - | 22.6% | 22.2% | 26.0% | 28.4% |
| ROE % | 30.0% | 55.3% | 8.4% | 9.9% | 10.4% | 11.4% | 16.7% | 18.6% | 18.1% | 16.8% | - | 13.1% | 11.3% | 12.2% | 12.6% |
| ROCE % | - | 84.5% | 13.9% | 17.1% | 15.1% | 18.0% | 17.1% | 17.8% | 16.6% | 16.2% | - | 12.1% | 9.1% | 11.6% | 12.5% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 7.94% | 12.86M | $3.35B |
| 2 | Vanguard Capital Management LLC | 5.99% | 9.69M | $2.52B |
| 3 | Vanguard Portfolio Management LLC | 4.58% | 7.41M | $1.93B |
| 4 | State Street Corporation | 4.14% | 6.71M | $1.75B |
| 5 | Principal Financial Group, Inc. | 3.08% | 4.98M | $1.30B |
| 6 | Alliancebernstein L.P. | 3.03% | 4.91M | $1.28B |
| 7 | Geode Capital Management, LLC | 2.78% | 4.51M | $1.17B |
| 8 | Linonia Partnership LP | 2.72% | 4.41M | $1.15B |
| 9 | AQR Capital Management, LLC | 2.16% | 3.50M | $910.31M |
| 10 | Price (T.Rowe) Associates Inc | 1.95% | 3.16M | $822.68M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for VEEV
Earnings Beat Could Be A Game Changer For Veeva Stock (VEEV) - simplywall.st
<a href="https://news.google.com/rss/articles/CBMiygFBVV95cUxNUHhrSFVRd2I2b2E5SzJUam5PQXpYaTktVGhXaUh4MWJUU1ZvWkpYWko5ajlZSDRkTjQ3bWVwRWpNcC1xOEt5S1BTcjJBTmZvd0o5TzVrZ1FwSHVPRnRLa0JocTdmYUhTSEZ2NC0tdnktSWpCSWtpV0pFOTJYbmdpdzNlWkQ2VEp3OElYSX…
A Look at Veeva Systems Inc (VEEV) After 3.7% Decline -- GF Value $291.08 vs Price $264.84 - gurufocus.com
<a href="https://news.google.com/rss/articles/CBMiugFBVV95cUxNSWE3ZEc3ODVXUHhmWXg3SEFJZGdaaDNhZW1oRlJrWEpEa01LNUlZZnBqbFlhUk4yNVgydENuRjEzcnIxdTB1eU1zd2MyUzh5Zk5BNlBUempreDJjNmp4aXpZczh4bWh1Z01LYVZtUmJGa2RiUlh5SXNrT0hITlY0WGNSc2NZb1FOQXlNQ1…
Michael Burry Remains Bullish on Veeva but Trimmed His Position. What This Means for VEEV Stock. - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMiogFBVV95cUxOTDlpY2xmWVBGblVSSHNRZnVCV0txUkNBQTBPSGZTcWFTMUlkcnJaVXF3QUhCNFNYbUNNZldGb2hRbWdkUktDNlRZcEtVTXR1NllKWHRqMXRrMW4xRGkwYVFQUklPWGhndlROc0hIZ1FIa1lyNzllNWxyTERHQms4N2VCSTF4YkxfMGdBNm…
Veeva Systems Inc. (VEEV) Stock Analysis: Strong Buy Ratings Amid Robust Revenue Growth - directorstalkinterviews.com
<a href="https://news.google.com/rss/articles/CBMizwFBVV95cUxQSFJiWHRnYnd0cktDaUlZNkJ5MXJ4eTVVNzZtT2Q2cGQ3dUxtdW5pNjdMdmU3SVpaejVhcFU0elRqcy10TlBpUUZnbU85UXlZX2xudVEzMEVkc3VuRzk3LUl6TnRNb3F5aGVsdVpDQUR5SEw1US12VmNWR19JZnBkRU1aQmowbDVDUUM2OD…
Veeva Systems Slides as Investors Digest Recent Earnings Rally - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMimwFBVV95cUxNNlZvYUhCUzd5VElxOXRhYlRjdVFoWHBCaUYwc0NYaURfY0lFZWJDUU5MY3BFeTMtdlVSZXk1Vkx5eG96QmdBWGxHS3hSOXVCeV9hbHJaM3BVNWhtQzZkS0xfX0pRR0NXOUlEUUJ4NDVJSzZXa0tUSkhFOEMwal9aSEJKUEpaM1BqaF9SNn…
Veeva Systems (NYSE: VEEV) director adds 493 shares - Stock Titan
<a href="https://news.google.com/rss/articles/CBMisAFBVV95cUxQV2J6b3NHU0N1LWg5OHptRExZTG1YNGVkd2dEMUJPRjFkWlNYY0lqM05oQU1kWkVZSE4wUTA2X1ZfYW80SVd5MWticXZqS3ZBMmJJSW83N0J1UHZEeHNDNVZNZ1JOQk9EMmtnZWU1bzRzczRCZDNxcno0R1hsZ2RrRGktdmVvSmluV1UtWD…
VEEV — Frequently Asked Questions
What is the current share price of Veeva Systems Inc. (VEEV)?
As of 2026-09-19 21:16 PDT, Veeva Systems Inc. (VEEV) trades at $264.84 on NYSE. Its 52-week range is $151.43 to $306.22.
What is the market capitalisation of VEEV?
Veeva Systems Inc. (VEEV) has a market capitalisation of $42.88B on NYSE.
What is the P/E ratio of VEEV?
VEEV trades at a trailing price-to-earnings (P/E) ratio of 43.49. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 5.80.
What is the return on equity (ROE) of VEEV?
VEEV has a return on equity (ROE) of 14.42%. Its return on capital employed (ROCE) is 12.48%.
Is VEEV a good stock to buy?
This page provides a data-driven analysis of Veeva Systems Inc. (VEEV), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.